M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Early Phase 1

Active, not recruiting

Conditions: Smoking Cessation

Interventions: Behavioral: Questionnaires
Procedure: Low Dose Computed Tomography Scan
Other: Shared Decision Making + Video
Behavioral: Cessation Counseling
Behavioral: Quitline
Drug: Nicotine Patch
Behavioral: Pharmacotherapy Discussion
Drug: Anti-Smoking Drug
Other: Carbon Monoxide (CO) Level Test
Behavioral: Tobacco Treatment Program

First Posted Date: 2017-02-23

Last Posted Date: 2025-04-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 630

Registration Number: NCT03059940

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-hodgkin Lymphoma
B-Lymphoid Malignancies

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells
Drug: AP1903

First Posted Date: 2017-02-17

Last Posted Date: 2024-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT03056339

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

Conditions: Multiple Endocrine Neoplasia
Hyperparathyroidism
Pancreatic Neuroendocrine Tumors

Interventions: Other: Genome Sequencing
Other: Data Review

First Posted Date: 2017-02-15

Last Posted Date: 2019-09-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT03053999

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism

Conditions: Primary Hyperparathyroidism

Interventions: Other: Retrospective Data Review

First Posted Date: 2017-02-14

Last Posted Date: 2020-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 250

Registration Number: NCT03052075

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Establishment of a Parathyroid Tissue Bank

Recruiting

Conditions: Parathyroid Disease

Interventions: Other: Tissue Samples

First Posted Date: 2017-02-13

Last Posted Date: 2020-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10000

Registration Number: NCT03051126

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease

Recruiting

Conditions: Endocrine Disease

Interventions: Other: Data Collection
Behavioral: Follow Up

First Posted Date: 2017-02-13

Last Posted Date: 2019-09-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15000

Registration Number: NCT03050762

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Blasts 20-30 Percent of Bone Marrow Nucleated Cells
Blasts 20-30 Percent of Peripheral Blood White Cells
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia With Multilineage Dysplasia
High Risk Myelodysplastic Syndrome
IPSS Risk Category Intermediate-2

Interventions: Drug: Azacitidine
Drug: Glutaminase Inhibitor CB-839

First Posted Date: 2017-02-09

Last Posted Date: 2024-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT03047993

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Active, not recruiting

Conditions: Multiple Endocrine Neoplasia Syndromes

Interventions: Behavioral: Questionnaires

First Posted Date: 2017-02-09

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT03048279

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

Recruiting

Conditions: Multiple Endocrine Neoplasia

First Posted Date: 2017-02-09

Last Posted Date: 2019-05-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 629

Registration Number: NCT03048266

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior

Completed

Conditions: Parathyroid Carcinoma
Parathyroid Neoplasm

Interventions: Other: Chart Review

First Posted Date: 2017-02-08

Last Posted Date: 2018-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03046524

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy